Cargando…
COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa
Designer nucleases allow specific and precise genomic modifications and represent versatile molecular tools for the correction of disease-associated mutations. In this study, we have exploited an ex vivo CRISPR/Cas9-mediated homology-directed repair approach for the correction of a frequent inherite...
Autores principales: | Hainzl, Stefan, Peking, Patricia, Kocher, Thomas, Murauer, Eva M., Larcher, Fernando, Del Rio, Marcela, Duarte, Blanca, Steiner, Markus, Klausegger, Alfred, Bauer, Johann W., Reichelt, Julia, Koller, Ulrich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675435/ https://www.ncbi.nlm.nih.gov/pubmed/28800953 http://dx.doi.org/10.1016/j.ymthe.2017.07.005 |
Ejemplares similares
-
An RNA-targeted therapy for dystrophic epidermolysis bullosa
por: Peking, Patricia, et al.
Publicado: (2017) -
Gene Editing for the Efficient Correction of a Recurrent COL7A1 Mutation in Recessive Dystrophic Epidermolysis Bullosa Keratinocytes
por: Chamorro, Cristina, et al.
Publicado: (2016) -
Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing
por: Bonafont, Jose, et al.
Publicado: (2021) -
A non-viral and selection-free COL7A1 HDR approach with improved safety profile for dystrophic epidermolysis bullosa
por: Kocher, Thomas, et al.
Publicado: (2021) -
5′RNA Trans-Splicing Repair of COL7A1 Mutant Transcripts in Epidermolysis Bullosa
por: Mayr, Elisabeth, et al.
Publicado: (2022)